We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.3B 47.09%
46,912,266
– –
INCY icon
2
Incyte
INCY
$25.5B
$2.75B 15.58%
36,154,117
+433
+0% +$32.9K
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$1.89B 10.71%
11,668,897
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12B
$632M 3.58%
7,620,494
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$591M 3.35%
41,923,486
+12,782
+0% +$239K
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$451M 2.56%
4,852,655
+311,051
+7% +$29.3M
ARGX icon
7
argenx
ARGX
$55.1B
$424M 2.41%
1,119,557
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.43B
$134M 0.76%
12,710,818
– –
KOD icon
9
Kodiak Sciences
KOD
$2.4B
$132M 0.75%
17,310,490
+1,379,445
+9% +$9.69M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$119M 0.68%
3,732,502
+417,737
+13% +$12.2M
ABCL icon
11
AbCellera Biologics
ABCL
$1.62B
$111M 0.63%
10,450,180
– –
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.5B
$107M 0.61%
1,499,213
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$94.6M 0.54%
1,409,784
– –
IMCR icon
14
Immunocore
IMCR
$1.68B
$94M 0.53%
2,520,730
– –
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$91.6M 0.52%
1,148,504
+249,662
+28% +$23.6M
CERS icon
16
Cerus
CERS
$575M
$85M 0.48%
16,067,558
+2,354,363
+17% +$11.8M
TVTX icon
17
Travere Therapeutics
TVTX
$5.11B
$80M 0.45%
3,300,009
– –
REPL icon
18
Replimune Group
REPL
$416M
$62.8M 0.36%
3,591,081
+1,979,378
+123% +$32.5M
TRDA icon
19
Entrada Therapeutics
TRDA
$229M
$59.3M 0.34%
4,865,819
+161,400
+3% +$1.22M
IGMS
20
DELISTED
IGM Biosciences
IGMS
$56.9M 0.32%
3,156,102
– –
KYMR icon
21
Kymera Therapeutics
KYMR
$8.6B
$56.7M 0.32%
2,879,825
+495,083
+21% +$11.6M
KRYS icon
22
Krystal Biotech
KRYS
$10.7B
$53M 0.3%
807,735
– –
PRLD icon
23
Prelude Therapeutics
PRLD
$347M
$52.8M 0.3%
10,123,824
– –
NRIX icon
24
Nurix Therapeutics
NRIX
$2.44B
$49.2M 0.28%
3,882,125
+1,428,043
+58% +$16.2M
LEGN icon
25
Legend Biotech
LEGN
$3.64B
$47.1M 0.27%
856,658
-1,152,341
-57% -$48.7M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Baker Bros. Advisors held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Baker Bros. Advisors added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Baker Bros. Advisors's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Baker Bros. Advisors fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q2 2022.
  • Baker Bros. Advisors's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.